[EN] FACTOR XI ACTIVATION INHIBITORS<br/>[FR] INHIBITEURS D'ACTIVATION DU FACTEUR XI
申请人:MERCK SHARP & DOHME
公开号:WO2021202254A1
公开(公告)日:2021-10-07
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.
NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
申请人:MENET Christel Jeanne Marie
公开号:US20130217664A1
公开(公告)日:2013-08-22
Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.
Wherein R
1
, L
1
, R
3
, R
4
, Cy, L
2
and R
5
are as defined herein.
AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS
申请人:Bryan Marian C.
公开号:US20160016948A1
公开(公告)日:2016-01-21
This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.